Acceleron Pharma EBIT

Acceleron Pharma (XLRN) currently reports a EBIT of $-260M as of September 2021. That compares with $-140M in the prior-year period — down 88.8% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Acceleron Pharma's EBIT history and peer comparisons.

Acceleron Pharma's EBIT decreased from $-140M to $-260M — a 88.8% year-over-year decrease (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acceleron Pharma's EBIT of $-260M is lower than the Healthcare sector average of $23B. That is roughly 101.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Acceleron Pharma reported $-260M in EBIT as of September 2021. That compares with $-140M in the prior-year period — down 88.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-260M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Acceleron Pharma, and consider following XLRN for alerts when major investors trade the stock.